EUVIMEDEUVIMED entdecken
Crossref

Efficacy and safety of once‐weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE‐D , AMPLITUDE‐L and AMPLITUDE‐S randomized controlled trials

Vanita R Aroda iD, Juan Pablo Frias iD, Linong Ji iD, Elisabeth Niemoeller, My-Liên Nguyên-Pascal, Karl Denkel iD, Melanie Espinasse, Hailing Guo, SeungJae Baek iD, JaeDuk Choi, Ildiko Lingvay iD

Diabetes, Obesity and Metabolism · 2023-08 · 25 (8) · 2084-2095

DOI: 10.1111/dom.15079 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 26.04.2023. Verfasst von Vanita R Aroda und 10 weiteren Autor:innen. Beteiligte Einrichtung: Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Metformin. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To evaluate the efficacy and safety of once‐weekly (QW) efpeglenatide in people with type 2 diabetes (T2D) suboptimally controlled with oral glucose‐lowering drugs and/or basal insulin (BI). Materials and Methods Three phase 3, multicentre, randomized controlled trials compared the efficacy and safety of QW efpeglenatide versus dulaglutide when added to metformin (AMPLITUDE‐D), efpeglenatide versus placebo when added to BI ± oral glucose‐lowering drugs (AMPLITUDE‐L) or metformin ± sulphonylurea (AMPLITUDE‐S). All trials were terminated early by the sponsor because of funding rather than safety or efficacy concerns.

Results

In AMPLITUDE‐D, non‐inferiority of efpeglenatide to dulaglutide 1.5 mg was shown in HbA1c reduction from baseline to week 56, least squares mean treatment difference (95% CI): 4 mg, −0.03% (−0.20%, 0.14%)/−0.35 mmol/mol (−2.20, 1.49); 6 mg, −0.08% (−0.25%, 0.09%)/−0.90 mmol/mol (−2.76, 0.96). The reductions in body weight (approximately 3 kg) from baseline to week 56 were similar across all treatment groups. In AMPLITUDE‐L and AMPLITUDE‐S, numerically greater reduction in HbA1c and body weight were observed at all doses of efpeglenatide than placebo. American Diabetes Association level 2 hypoglycaemia (< 54 mg/dL [< 3.0 mmol/L]) was reported in few participants across all treatment groups (AMPLITUDE‐D, ≤ 1%; AMPLITUDE‐L, ≤ 10%; and AMPLITUDE‐S, ≤ 4%). The adverse events profile was consistent with other glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs); gastrointestinal adverse events were most frequent in all three studies.

Conclusions

In people with T2D suboptimally controlled with oral glucose‐lowering drugs and/or BI, QW efpeglenatide was non‐inferior to dulaglutide in terms of HbA1c reduction and showed numerically greater improvements than placebo in glycaemic control and body weight, with safety consistent with the GLP‐1 RA class.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2MetforminHumansHypoglycemic AgentsGlycated HemoglobinBlood GlucoseRandomized Controlled Trials as TopicGlucagon-Like Peptide 1Glucagon-Like PeptidesBody WeightGlucoseImmunoglobulin Fc FragmentsTreatment OutcomeRecombinant Fusion ProteinsProline

Stichwörter der Autor:innen

GLP-1 receptor analoguedulaglutideefpeglenatideglycaemic controltype 2 diabetes

Substanzen

Hypoglycemic AgentsGlycated HemoglobinBlood GlucoseMetforminGlucagon-Like Peptide 1Glucagon-Like PeptidesGlucoseImmunoglobulin Fc FragmentsRecombinant Fusion Proteinsefpeglenatide

Autor:innen und Institutionen

  • Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Velocity Clinical Research, Los Angeles, California, USA.
  • Peking University People's Hospital, Beijing, China.
  • Sanofi, Frankfurt, Germany.
  • Sanofi, Chilly-Mazarin, France.
  • Sanofi, Bridgewater, New Jersey, USA.

ORCID-Profile: Vanita R Aroda, Juan Pablo Frias, Linong Ji, Karl Denkel, SeungJae Baek, Ildiko Lingvay

Förderung

  • Sanofi

Zitieren

APA

Aroda, V. R., Frias, J. P., Ji, L., Niemoeller, E., Nguyên-Pascal, M. L., Denkel, K., Espinasse, M., Guo, H., Baek, S., Choi, J., & Lingvay, I. (2023). Efficacy and safety of once‐weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE‐D , AMPLITUDE‐L and AMPLITUDE‐S randomized controlled trials. Diabetes, Obesity and Metabolism, 25(8), 2084-2095. https://doi.org/10.1111/dom.15079

Vancouver

Aroda VR, Frias JP, Ji L, Niemoeller E, Nguyên-Pascal ML, Denkel K, et al. Efficacy and safety of once‐weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE‐D , AMPLITUDE‐L and AMPLITUDE‐S randomized controlled trials. Diabetes, Obesity and Metabolism. 2023;25(8):2084-2095. doi:10.1111/dom.15079

BibTeX
@article{Aroda2023,
  author = {Aroda, Vanita R and Frias, Juan Pablo and Ji, Linong and Niemoeller, Elisabeth and Nguyên-Pascal, My-Liên and Denkel, Karl and Espinasse, Melanie and Guo, Hailing and Baek, SeungJae and Choi, JaeDuk and Lingvay, Ildiko},
  title = {Efficacy and safety of once‐weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE‐D , AMPLITUDE‐L and AMPLITUDE‐S randomized controlled trials},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  volume = {25},
  number = {8},
  pages = {2084--2095},
  doi = {10.1111/dom.15079}
}
Kostenlos starten →